



SHAREABLE PDF

Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients

Hai-qiong Yu^{1,9}, Bao-qing Sun^{2,9}, Zhang-fu Fang^{1,2,3,9}, Jin-cun Zhao^{2,9}, Xiao-yu Liu^{1,9}, Yi-min Li^{2,9}, Xi-zhuo Sun^{3,9}, Hong-feng Liang^{4,9}, Bei Zhong^{5,9}, Zhi-feng Huang^{2,9}, Pei-yan Zheng², Li-feng Tian⁶, Hui-Qi Qu⁶, De-chen Liu⁷, Er-yi Wang^{1,3}, Xiao-jun Xiao¹, Shi-yue Li², Feng Ye², Li Guan³, Dong-sheng Hu⁷, Hakon Hakonarson^{6,8,10}, Zhi-gang Liu^{1,10} and Nan-shan Zhong^{2,10}

Affiliations: ¹State Key Laboratory of Respiratory Disease for Allergy at Shenzhen University, Shenzhen Key Laboratory of Allergy and Immunology, Shenzhen University School of Medicine, Shenzhen, China. ²State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. ³Dept of Respiriology and Allergy, Third Affiliated Hospital of Shenzhen University, Shenzhen, China. ⁴Yangjiang People's Hospital, Yangjiang, China. ⁵Dept of Infectious Disease, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China. ⁶Center for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA. ⁷Dept of Preventive Medicine, Shenzhen University Health Sciences Center, Shenzhen, China. ⁸Divisions of Human Genetics and Pulmonary Medicine, Dept of Pediatrics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ⁹These authors contributed equally to this work. ¹⁰Hakon Hakonarson, Zhi-gang Liu and Nan-shan Zhong are joint lead authors.

Correspondence: Nan-shan Zhong, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, 151 Yanjiang Rd., Guangzhou (510120), China. E-mail: nanshan@vip.163.com

 @ERSpublications

Humoral immune response to SARS-CoV-2 showed an early response of IgA, instead of IgM, in COVID-19 patients. As highlighted by this study, enhanced IgA responses observed in severe COVID-19 might confer damaging effects in severe COVID-19. <https://bit.ly/3fA7c1I>

Cite this article as: Yu H-qiong, Sun B-qing, Fang Z-fu, *et al.* Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients. *Eur Respir J* 2020; 56: 2001526 [<https://doi.org/10.1183/13993003.01526-2020>].

This single-page version can be shared freely online.

To the Editor:

In comparison to severe acute respiratory syndrome coronavirus (SARS-CoV), SARS-CoV-2 appears to be more contagious [1], and coronavirus disease 2019 (COVID-19) patients demonstrate varied clinical manifestations distinct from those seen in patients with SARS-CoV and Middle East respiratory syndrome coronavirus infections [2]. Collective results from the clinical and epidemiological observations suggest a distinct viral–host interaction in COVID-19 patients. Profiling of the antibody response during SARS-CoV-2 infection may help improve our understanding of the viral–host interaction and the immunopathological mechanisms of the disease.